Skip to content

Interventional effect of new double bronchodilators on patients with COPD under the management of mobile medical system

Interventional effect of new double bronchodilators on patients with COPD under the management of mobile medical system

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033901
Enrollment
Unknown
Registered
2020-06-16
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Group A (Olexin Group):Olexin 1 suck 1 / day
Mobile medical network management
Group B (Tiotropium Group):Tiotropium 1 suction 1 / day
Group C (Shuli Die Group):Salmeterol fluticasone 1 suction / time, 2 times / day
Group D (Olexin Control Group):Olexin 1 suction 1/day, routine outpatient follow-up management

Sponsors

People's Hospital of Shapingba District of Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients had FEV1 / FVC = 40 years old, according to the 2013 Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease, that is, the patient s lung function after inhalation of bronchodilators meets the first second effort the percentage of expiratory volume FEV1 and forced vital capacity FVC is less than 70%, and the forced expiratory volume FEV1 in the first second accounts for less than 80% of the predicted value. It is clinically diagnosed as COPD patients. Possess language communication ability, normal hearing, normal cognitive function, personal smart phone, use WeChat, APP and other electronic devices.

Exclusion criteria

Exclusion criteria: 1. Asthma, bronchiectasis, tuberculosis or diffuse panbronchiolitis; 2. Glaucoma, arrhythmia, urinary retention; 3. Severe comorbidities and complications such as pulmonary encephalopathy, severe cardio-cerebrovascular disease; 4. Those taking sedatives and antidepressants; 5. Those who have a history of mental illness or severe cognitive impairment.

Design outcomes

Primary

MeasureTime frame
Lung function;6 minutes walking test distance;SGRQ St. George's Respiratory Questionnaire;Incidence of adverse reactions;Number of acute exacerbations per year;Economic cost;

Countries

China

Contacts

Public ContactChen Dongling

People's Hospital of Shapingba District of Chongqing

546683921@qq.com+86 15922895654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026